Graham Capital Management L.P. Buys New Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Graham Capital Management L.P. acquired a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 92,748 shares of the company's stock, valued at approximately $431,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. National Bank of Canada FI raised its stake in shares of GoodRx by 34.9% in the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after purchasing an additional 2,151 shares in the last quarter. Gagnon Securities LLC increased its holdings in GoodRx by 9.9% in the fourth quarter. Gagnon Securities LLC now owns 69,867 shares of the company's stock valued at $325,000 after buying an additional 6,266 shares during the last quarter. Swiss National Bank raised its stake in GoodRx by 4.1% during the fourth quarter. Swiss National Bank now owns 161,400 shares of the company's stock valued at $751,000 after buying an additional 6,400 shares in the last quarter. RPO LLC bought a new position in GoodRx during the 4th quarter worth approximately $52,000. Finally, Versor Investments LP bought a new position in GoodRx during the 4th quarter worth approximately $54,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GDRX has been the topic of several research reports. The Goldman Sachs Group dropped their price target on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Wells Fargo & Company dropped their target price on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. UBS Group decreased their price target on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Finally, Truist Financial dropped their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $6.55.

GoodRx Stock Performance

GDRX stock traded up $0.02 during trading on Tuesday, reaching $3.97. 923,363 shares of the company's stock were exchanged, compared to its average volume of 1,386,717. GoodRx Holdings, Inc. has a 1-year low of $3.68 and a 1-year high of $9.26. The firm has a market cap of $1.42 billion, a PE ratio of -132.33, a P/E/G ratio of 2.46 and a beta of 1.24. The company's fifty day moving average price is $4.43 and its 200-day moving average price is $4.63. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. The firm had revenue of $202.97 million during the quarter, compared to analyst estimates of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. GoodRx's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.08 EPS. On average, research analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.